BRIDGEWATER, N.J. & CADEMPINO, Switzerland - Amneal Pharmaceuticals, Inc. (NASDAQ: NASDAQ:AMRX) has announced an exclusive licensing agreement with Zambon Biotech SA for the commercialization of IPX203 in the European Union, United Kingdom, and Switzerland.
IPX203 is a novel extended-release oral treatment for Parkinson’s disease, currently under review by the U.S. Food and Drug Administration.
Zambon Biotech, a company with a strong presence in the European neurology market, will seek regulatory approval for IPX203 in these regions. The financial details of the partnership remain undisclosed. This deal aligns with Amneal's strategic aim to ensure global access to its Parkinson's disease treatments.
IPX203 is designed to provide improved control of motor symptoms for patients with Parkinson’s disease compared to immediate-release carbidopa/levodopa. The medication's formulation includes both immediate-release and extended-release components to enhance symptom management.
The licensing agreement is part of Amneal's broader strategy to make IPX203 available worldwide, complementing a previous agreement with Knight Therapeutics Inc. for the drug's commercialization in Canada and Latin America.
Parkinson’s disease is a growing global concern with over 10 million individuals affected, characterized by movement disorders such as tremors and impaired balance. The condition is not fatal but can lead to significant morbidity and disability.
Amneal Pharmaceuticals is a fully integrated global pharmaceutical company, while Zambon Biotech SA is a subsidiary of Zambon, a multinational chemical-pharmaceutical company with a focus on innovative medicines for patient care.
This partnership is expected to leverage Zambon's established neurology footprint in Europe to facilitate the introduction of IPX203 to the market, potentially improving treatment options for Parkinson’s patients across the region.
The information provided is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.